Σάββατο 29 Απριλίου 2017

Progress and challenges in the treatment of small cell lung cancer

Abstract

Small cell lung cancer (SCLC) is a very aggressive malignancy characterized by high cellular proliferation and early metastatic spread. In fact, although SCLC is a chemosensitive and radiosensitive disease, the initial responsiveness to chemotherapy is usually followed by development of resistance and the prognosis remains poor with a median survival of less than 12 months in patients with extensive disease (ED-SCLC). Furthermore, no significant progress has been made over the last years, with no newly approved drug. For all these reasons, SCLC represents for the oncologists a major challenge and an exciting field of clinical research. In this review, we analyze the most promising advances in development for SCLC with a special focus on antiangiogenic treatments, immunotherapy, novel chemotherapeutic and targeted agents.



from Cancer via ola Kala on Inoreader http://ift.tt/2pIPu5C
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου